Physician profile
Ernest Graypel
NPI 1265723407
$10,015.07
in general payments reported to CMS, 2019-2025
37 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $1,154 · 2021: $1,246 · 2022: $895 · 2023: $1,530 · 2024: $1,972 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,577 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.73 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,264.63 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,132.40 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $929.60 | 2022-2025 | Caplyta |
| Alkermes, INC. | $744.27 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $721.74 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $605.77 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $467.81 | 2019-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $465.48 | 2019-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $459.35 | 2020-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $423.46 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $356.98 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $307.49 | 2019-2025 | Uzedy, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $199.78 | 2019-2021 | |
| Axsome Therapeutics, INC. | $192.95 | 2024-2025 | Auvelity |
| Alpha Cognition USA, INC. | $189.99 | 2025 | Zunveyl |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $174.41 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $165.74 | 2022-2024 | Aplenzin |
| Orexo US, INC. | $151.36 | 2020-2021 | |
| Almatica Pharma LLC | $135.03 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $121.06 | 2022-2025 | Dyanavel Xr |
| Eisai INC. | $106.49 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.60 | 2019 | |
| Livanova USA, INC. | $86.49 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $83.81 | 2024-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $73.91 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $60.56 | 2022-2025 | Qelbree |
| Neos Therapeutics, LP | $55.15 | 2025 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $43.66 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.63 | 2023 | Abilify Asimtufii |
| Indivior INC. | $36.08 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.67 | 2022 | |
| Brainsway USA INC | $20.63 | 2024 | Brainsway Deep Tms System |
| Ge Healthcare | $18.83 | 2023 | |
| Validus Pharmaceuticals LLC | $18.34 | 2020 | |
| Corium, LLC | $17.60 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Graypel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.